Coronary artery calcification is probably the main determinant of the poor outcome of percutaneous coronary interventions and is associated with higher rates of adverse events. There are currently different balloon or specific device-based plaque modification techniques available. Knowing their characteristics and proper use is key for the optimal treatment of calcified lesions. This position paper—promoted by the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC)—describes existing plaque modification techniques currently available and proposes an algorithm for the management of calcified lesions.

At 3 years in EBC MAIN and 5 years in EBC TWO, the provisional strategy did just as well as—or better than—dual stenting.

In this study, patients with ACS had a main composite outcome that was not different 5 years after TiNO-coated stent or EES.

Data at the end of the resorption period of DREAMS 3G showed that the third-generation bioresorbable magnesium scaffold is clinically safe and effective, making it a possible alternative to DES.

Titanium-nitride-oxide (TiNO)-coated stents show faster strut coverage compared with drug-eluting stents without excessive intimal-hyperplasia observed in bare metal stents. It is important to study long-term clinical outcomes after treatment of patients with an acute coronary syndrome (ACS) by TiNO-coated stents, which are neither drug-eluting stents nor bare metal stents.

At 18 months post-percutaneous coronary intervention (PCI), the TIDES-ACS results reveal that the Optimax nitride-oxide coated stent is superior in patients with acute coronary syndrome compared to one of the top drug-eluting stents used in current interventional cardiology.

Despite the huge progress in the stent technology, no ideal stent exists until now. It is expected that some of the existing problems will be overcome in the close future, as we can especially remark in the numerous patents filled in the last few years.

In long CTO PCIs, OS is more frequently used than single stenting, especially in more complex procedures. Clinical outcomes at a mid-term follow-up are favorable. Using newer generation DES, overlapping was not an independent predictor of MACE; however, a trend toward a higher event rate was observed in the OS group.

Via a series of case presentations, learn more about the dual drug delivery from DES and DCB platform to treat diabetes mellitus patients. Understand its efficiency in a complex setting and see how a no-polymer DES and DCB platform can fill the gaps of the unmet clinical needs.

Explore the latest trends in percutaneous coronary intervention (PCI) in this session, focusing on stentless PCI and the role of sustained limus release technology. Join the discussion on how sustained limus release can expand the indications for drug-eluting balloons (DEB) and minimize the use of metal stents, gain insights into the importance of vessel preparation and learn which tools to utilize in specific scenarios.

Check out this session to learn more about polymer-free treatment options with DCB and DES, increasing DCB in the daily cathlab routine, and the possibility of including BRS in the daily PCI routine.

Intracoronary physiology guidance, post-PCI physiology, the increasing use of imaging to improve the clinical outcome of the patient, new technologies such as drug-coated balloons, and much more.

The FP-WM device showed significantly less thrombus and reduced inflammation in a challenging canine model. Mechanistic studies indicated that the fluoropolymer-coated device binds more albumin, leading to reduced platelet binding, less inflammation, and greater EC.

The authors conclude that long-term safety and effectiveness of DCB therapy in three high-risk cohorts demonstrated low reintervention rates and no safety issues for the long lesion and CTO groups. Rates of de novo ISR and composite safety outcomes were modest in the ISR cohort.

Mid-term outcomes of stent-less PCI using RA/DCB for de-novo lesions in HD patients might be comparable to those in non-HD patients, suggesting efficacy of pretreatment of RA prior to DCB treatment in HD patients.

The LimFlow System for TADV (Transcatheter Arterialization of Deep Veins) is designed to reestablish blood flow in deep veins for “no-option” CLTI patients who have exhausted all other treatment methods and face major amputation of their lower limb. The therapy is designed to prevent amputation, which is associated with significant complications, mortality, and deterioration of quality of life. CLTI affects up to four million Americans and disproportionately impacts minority and underserved patients, resulting in more than 150,000 major amputations per year in the U.S.

This study evaluates SELUTION SLR in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption (IDE) approval in the US in August 2022. SELUTION SLR is the first and only limus release drug-eluting balloon (DEB) to receive FDA IDE approval for SFA and PPA indications.

Interventional cardiology achieved huge improvements in the past decades, and stent technology reached high standards in terms of acute and long-term performance. But these devices are not the panacea of coronary artery disease treatment. Any planned intervention in your patient should be justified by a real need-this is clear cut for any physician! But we want to stress that any prosthesis (foreign body) you would like to implant should be justified by a clear benefit on the very long term. When we propose it, try to predict how many device-related events are expected after 10 years, then ask yourself: is it worth it?

In-stent restenosis concerning the coronary artery refers to the blood clotting-caused re-narrowing of the blocked section of the artery, which is opened using a stent. The failure rate for stents is in the range of 10% to 15%, where they do not remain open, thereby leading to about 40% of the patients with stent implantations requiring repeat procedure within one year, despite increased risk factors and the administration of expensive medicines. Hence, today stent restenosis is a significant cause of deaths globally. Monitoring and treatment matter a lot when it comes to early diagnosis and treatment.

The stent-grafts with drug-loaded membranes exhibited a slow drug-release profile more for than 70 h and low water permeability at 158.33 ± 17.56 mL/cm2·min. The combination of PTX and MET inhibited the growth of human umbilical vein endothelial cells. Therefore, it was possible to generate dual-drug-loaded woven vascular stent-grafts to achieve the more effective treatment of Abdominal Aortic Aneurysm.